You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Mounjaro ® (tirzepatide) injection
2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Has dysesthesia been reported in patients taking Mounjaro® (tirzepatide)?
In the SURPASS-1 and -5 studies in adults with type 2 diabetes, dysesthesia was reported by 0.4%, 0.4%, and 0.4% of participants treated with tirzepatide 5 mg, 10 mg, and 15 mg, respectively. No events were reported by patients receiving placebo.
See important safety information, including boxed warning, in the attached prescribing information.
Dysesthesia
Dysesthesia is a touch-based disorder that can result in feelings of pain, itchiness, tingling, shock, burning, and other uncomfortable sensations in the skin.1
In 2 studies comparing tirzepatide to placebo in adults with type 2 diabetes (SURPASS-1 and SURPASS-5), dysesthesia was reported by 0.4%, 0.4%, and 0.4% of participants treated with tirzepatide 5 mg, 10 mg, and 15 mg, respectively. No events were reported by patients receiving placebo.2
Enclosed Prescribing Information
References
1Dysesthesia. Cleveland Clinic. Updated May 12, 2023. Accessed November 13, 2024. https://my.clevelandclinic.org/health/symptoms/24989-dysesthesia
2Mounjaro [package insert]. Indianapolis, IN: Eli Lilly and Company; 2024.
Date of Last Review: December 04, 2024